Bilayer Dapagliflozin-Metformin Tablets for Dual Release Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bilayer tablet formulations of dapagliflozin and metformin face issues with undesired release profiles due to diffusion barriers, solubility differences, and prolonged onset of action, affecting patient compliance and efficacy.
Innovation Solution
A bilayer tablet formulation with specific proportions of metformin in both immediate and extended release layers, using excipients like microcrystalline cellulose, polyvinylpyrrolidone, croscarmellose sodium, and magnesium stearate, to enhance dissolution and compressibility, ensuring rapid immediate release and sustained extended release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release layer is designed to diffuse fast, then rapid drug onset is achieved, but diffusion barrier forms that prevents extended release layer from functioning properly
Solution Approach 1:
The tablet is divided into two distinct layers: an immediate release layer and an extended release layer. This segmentation allows each layer to independently control the release kinetics of active ingredients without interfering with the other layer's function, resolving the contradiction between rapid onset and sustained release control.
Solution Approach 2:
Each layer is formulated with specific excipients and polymers tailored to its release function. The immediate release layer contains excipients promoting rapid dissolution, while the extended release layer contains polymers providing controlled release. This local optimization of properties ensures each layer performs its intended function without creating diffusion barriers that would compromise overall release profile control.
2Duration of action of moving object
If extended release polymers are used to maintain blood sugar balance, then duration of action is improved, but diffusion barrier surrounds tablet preventing immediate release layer from diffusing adequately
Solution Approach 1:
By separating the tablet into two functional layers, the invention enables the extended release layer to provide prolonged glucose control through controlled polymer degradation, while the immediate release layer simultaneously provides rapid onset. The physical separation prevents the extended release polymers from forming a barrier that would impede immediate release diffusion.
Solution Approach 2:
The invention transitions from a single-layer system to a two-layer system, adding a dimensional aspect to the formulation. This structural change allows simultaneous achievement of rapid onset (immediate release layer) and prolonged duration (extended release layer) without the trade-off present in single-layer systems.
3Reliability
If solubility differences between metformin and dapagliflozin are addressed, then dissolution is improved, but formulation complexity increases
Solution Approach 1:
The invention applies local quality optimization by formulating each layer with excipients specifically selected for the solubility characteristics of the active ingredients it contains. The immediate release layer uses excipients that enhance dissolution of both metformin and dapagliflozin, while the extended release layer uses polymers and excipients optimized for controlled release. This localized formulation approach improves dissolution performance without requiring complex overall formulation structures.
Data Source
AI summary
The invention relates to bilayer tablet formulations comprising dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.